A validated antibody panel for the characterization of tau post-translational modifications

Abstract Background Tau is a microtubule-binding protein, which is subject to various post-translational modifications (PTMs) including phosphorylation, methylation, acetylation, glycosylation, nitration, sumoylation and truncation. Aberrant PTMs such as hyperphosphorylation result in tau aggregatio...

Full description

Bibliographic Details
Main Authors: Ebru Ercan, Sameh Eid, Christian Weber, Alexandra Kowalski, Maria Bichmann, Annika Behrendt, Frank Matthes, Sybille Krauss, Peter Reinhardt, Simone Fulle, Dagmar E. Ehrnhoefer
Format: Article
Language:English
Published: BMC 2017-11-01
Series:Molecular Neurodegeneration
Subjects:
Tau
Online Access:http://link.springer.com/article/10.1186/s13024-017-0229-1
id doaj-437f516a84194ce1aac4371077d7c061
record_format Article
spelling doaj-437f516a84194ce1aac4371077d7c0612020-11-25T00:53:00ZengBMCMolecular Neurodegeneration1750-13262017-11-0112111910.1186/s13024-017-0229-1A validated antibody panel for the characterization of tau post-translational modificationsEbru Ercan0Sameh Eid1Christian Weber2Alexandra Kowalski3Maria Bichmann4Annika Behrendt5Frank Matthes6Sybille Krauss7Peter Reinhardt8Simone Fulle9Dagmar E. Ehrnhoefer10BioMed X Innovation CenterBioMed X Innovation CenterBioMed X Innovation CenterAbbVie GmbH&Co KGBioMed X Innovation CenterBioMed X Innovation CenterGerman Center for Neurodegenerative Diseases (DZNE)German Center for Neurodegenerative Diseases (DZNE)AbbVie GmbH&Co KGBioMed X Innovation CenterBioMed X Innovation CenterAbstract Background Tau is a microtubule-binding protein, which is subject to various post-translational modifications (PTMs) including phosphorylation, methylation, acetylation, glycosylation, nitration, sumoylation and truncation. Aberrant PTMs such as hyperphosphorylation result in tau aggregation and the formation of neurofibrillary tangles, which are a hallmark of Alzheimer’s disease (AD). In order to study the importance of PTMs on tau function, antibodies raised against specific modification sites are widely used. However, quality control of these antibodies is lacking and their specificity for particular modifications is often unclear. Methods In this study, we first designed an online tool called ‘TauPTM’, which enables the visualization of PTMs and their interactions on human tau. Using TauPTM, we next searched for commercially available antibodies against tau PTMs and characterized their specificity by peptide array, immunoblotting, electrochemiluminescence ELISA and immunofluorescence technologies. Results We demonstrate that commercially available antibodies can show a significant lack of specificity, and PTM-specific antibodies in particular often recognize non-modified versions of the protein. In addition, detection may be hindered by other PTMs in close vicinity, complicating the interpretation of results. Finally, we compiled a panel of specific antibodies and show that they are useful to detect PTM-modified endogenous tau in hiPSC-derived neurons and mouse brains. Conclusion This study has created a platform to reliably and robustly detect changes in localization and abundance of post-translationally modified tau in health and disease. A web-based version of TauPTM is fully available at http://www.tauptm.org .http://link.springer.com/article/10.1186/s13024-017-0229-1TauPost-translational modificationAntibody validationAlzheimer’s disease
collection DOAJ
language English
format Article
sources DOAJ
author Ebru Ercan
Sameh Eid
Christian Weber
Alexandra Kowalski
Maria Bichmann
Annika Behrendt
Frank Matthes
Sybille Krauss
Peter Reinhardt
Simone Fulle
Dagmar E. Ehrnhoefer
spellingShingle Ebru Ercan
Sameh Eid
Christian Weber
Alexandra Kowalski
Maria Bichmann
Annika Behrendt
Frank Matthes
Sybille Krauss
Peter Reinhardt
Simone Fulle
Dagmar E. Ehrnhoefer
A validated antibody panel for the characterization of tau post-translational modifications
Molecular Neurodegeneration
Tau
Post-translational modification
Antibody validation
Alzheimer’s disease
author_facet Ebru Ercan
Sameh Eid
Christian Weber
Alexandra Kowalski
Maria Bichmann
Annika Behrendt
Frank Matthes
Sybille Krauss
Peter Reinhardt
Simone Fulle
Dagmar E. Ehrnhoefer
author_sort Ebru Ercan
title A validated antibody panel for the characterization of tau post-translational modifications
title_short A validated antibody panel for the characterization of tau post-translational modifications
title_full A validated antibody panel for the characterization of tau post-translational modifications
title_fullStr A validated antibody panel for the characterization of tau post-translational modifications
title_full_unstemmed A validated antibody panel for the characterization of tau post-translational modifications
title_sort validated antibody panel for the characterization of tau post-translational modifications
publisher BMC
series Molecular Neurodegeneration
issn 1750-1326
publishDate 2017-11-01
description Abstract Background Tau is a microtubule-binding protein, which is subject to various post-translational modifications (PTMs) including phosphorylation, methylation, acetylation, glycosylation, nitration, sumoylation and truncation. Aberrant PTMs such as hyperphosphorylation result in tau aggregation and the formation of neurofibrillary tangles, which are a hallmark of Alzheimer’s disease (AD). In order to study the importance of PTMs on tau function, antibodies raised against specific modification sites are widely used. However, quality control of these antibodies is lacking and their specificity for particular modifications is often unclear. Methods In this study, we first designed an online tool called ‘TauPTM’, which enables the visualization of PTMs and their interactions on human tau. Using TauPTM, we next searched for commercially available antibodies against tau PTMs and characterized their specificity by peptide array, immunoblotting, electrochemiluminescence ELISA and immunofluorescence technologies. Results We demonstrate that commercially available antibodies can show a significant lack of specificity, and PTM-specific antibodies in particular often recognize non-modified versions of the protein. In addition, detection may be hindered by other PTMs in close vicinity, complicating the interpretation of results. Finally, we compiled a panel of specific antibodies and show that they are useful to detect PTM-modified endogenous tau in hiPSC-derived neurons and mouse brains. Conclusion This study has created a platform to reliably and robustly detect changes in localization and abundance of post-translationally modified tau in health and disease. A web-based version of TauPTM is fully available at http://www.tauptm.org .
topic Tau
Post-translational modification
Antibody validation
Alzheimer’s disease
url http://link.springer.com/article/10.1186/s13024-017-0229-1
work_keys_str_mv AT ebruercan avalidatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT sameheid avalidatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT christianweber avalidatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT alexandrakowalski avalidatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT mariabichmann avalidatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT annikabehrendt avalidatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT frankmatthes avalidatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT sybillekrauss avalidatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT peterreinhardt avalidatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT simonefulle avalidatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT dagmareehrnhoefer avalidatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT ebruercan validatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT sameheid validatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT christianweber validatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT alexandrakowalski validatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT mariabichmann validatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT annikabehrendt validatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT frankmatthes validatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT sybillekrauss validatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT peterreinhardt validatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT simonefulle validatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
AT dagmareehrnhoefer validatedantibodypanelforthecharacterizationoftauposttranslationalmodifications
_version_ 1725239648104480768